1-(AMINOALKYL)-2-PHENYLINDOLES AS NOVEL PURE ESTROGEN ANTAGONISTS

被引:85
作者
VONANGERER, E
KNEBEL, N
KAGER, M
GANSS, B
机构
[1] Institut fur Pharmazie, niversitdt Regensburg, U
关键词
D O I
10.1021/jm00171a045
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A number of 1-(ω-aminoalkyl)-5-hydroxy-2-(4-hydroxyphenyl)indoles were synthesized and studied for their binding affinities for the calf uterine estrogen receptor and estrogen antagonistic activities. Highest binding affinities were found with derivatives bearing a methyl group in position 3 and a hexamethylene chain between the indole and amino nitrogen atoms. Values for relative binding affinity (RBA) are between 20 and 30 for derivatives 5b, 5c, 5f, and 5h (17β-estradiol = 100). In the mouse uterine weight test, no significant agonistic (estrogenic) activity was observed up to a daily dose of 125 μg/animal, except for derivatives 5c, 5j, and 51. 2-Phenylindoles with amino (5b), pyrrolidino (5f), piperidino (5h), and morpholino (5k) groups as the amino function completely suppressed estrone-stimulated uterine growth as a dose of 125 μg/animal (100% antagonism). Therefore, these derivatives can be considered as first examples of nonsteroidal pure antiestrogens. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:2635 / 2640
页数:6
相关论文
共 20 条
[1]  
BOWLER J, 1989, Steroids, V54, P71, DOI 10.1016/0039-128X(89)90076-7
[2]  
FERNANDEZPOL JA, 1986, CANCER RES, V46, P5153
[3]   THE PHARMACOLOGY AND CLINICAL USES OF TAMOXIFEN [J].
FURR, BJA ;
JORDAN, VC .
PHARMACOLOGY & THERAPEUTICS, 1984, 25 (02) :127-205
[4]  
JORDAN VC, 1980, CANCER TREAT REP, V64, P745
[5]   DOSE-RELATED EFFECTS OF NON-STEROIDAL ANTIOESTROGENS AND ESTROGENS ON MEASUREMENT OF CYTOPLASMIC ESTROGEN RECEPTORS IN RAT AND MOUSE UTERUS [J].
JORDAN, VC ;
ROWSBY, L ;
DIX, CJ ;
PRESTWICH, G .
JOURNAL OF ENDOCRINOLOGY, 1978, 78 (01) :71-81
[6]   PLATINUM COMPLEXES WITH BINDING-AFFINITY FOR THE ESTROGEN-RECEPTOR [J].
KNEBEL, N ;
VONANGERER, E .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (09) :1675-1679
[7]  
KNEBEL N, 1988, THESIS REGENSBURG
[8]  
LEGAULTPOISSON S, 1979, CANCER TREAT REP, V63, P1839
[9]  
MAASS H, 1980, CANCER, V46, P2783
[10]  
PALM M, IN PRESS ARCH PHARM